Screener
Kura Oncology KURA Cost Of Product Sales
Cost Of Product Sales at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept kura:CostOfProductSales.
The source filing: Kura Oncology’s 10-K, filed March 5, 2026.
- Filed
- Mar 5, 2026, 7:31 AM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-092567
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 | Years Ended December 31, 2023 |
|---|---|---|---|
| Collaboration revenue | 65,350 | 53,883 | — |
| Total revenue | 67,482 | 53,883 | — |
| Operating Expenses | |||
| Cost of product sales | 57 | — | — |
| Research and development | 251,074 | 169,967 | 115,235 |
| Selling, general and administrative | 119,982 | 77,111 | 50,569 |
| Total operating expenses | 371,113 | 247,078 | 165,804 |
| Loss from operations | (303,631) | (193,195) | (165,804) |
Item 16. Form 10-K Summary.
FAQ
- What is Kura Oncology's cost of product sales?
- Kura Oncology (KURA) reported cost of product sales of $14.25K in Q4 2025.
- What does cost of product sales mean?
- This metric represents the direct costs attributable to the production and delivery of goods sold by the company during the reporting period. It encompasses raw materials, direct labor, and manufacturing overheads required to bring products to a saleable state. For a clinical-stage biopharmaceutical company, this figure reflects the scalability and efficiency of commercialized product manufacturing.
Ask your AI about Kura Oncology's cost of product sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude